tirzepatide maximum weight loss surmount trials reduction over time in tirzepatide‐treated participants by early weight response: Post hoc analysis in SURMOUNT‐1 - Ard - 2025 - Diabetes, Obesity and Metabolism Tirzepatide for maintenance of bodyweight

Levels should be in the normal or high-normal range if supplementation is adequate

Important safety information Certain GLP-1 therapies such as semaglutide (the active ingredient in Ozempic, Rybelsus, and Wegovy), liraglutide (the active ingredient in Saxenda and Victoza), and tirzepatide (the active ingredient in Mounjaro and Zepbound) may increase the likelihood of developing thyroid gland tumors, including MTC, a type of thyroid cancer

Long-term data indicated sustained weight loss maintenance over three years

But they are not identical, and one common question is whether tirzepatide is actually better than semaglutide

Most people experience minimal appetite suppression at 2.5mg